NCT04446416 2026-04-09
Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients
NaviFUS Corporation
Phase NA Completed
Clinical Trials
46 trialsNCT05919264 2026-04-09
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Parabilis Medicines, Inc.
Phase 1/2 Recruiting
NCT06329570 2026-04-09
Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)
NaviFUS Corporation
Phase 1/2 Recruiting
NCT06496971 2026-04-09
A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients
NaviFUS Corporation
Phase 3 Recruiting
NCT07297212 2026-03-12
A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma
BioNTech SE
Phase 2 Recruiting
NCT06047379 2026-03-02
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
Phase 1/2 Recruiting
NCT06061809 2026-02-12
N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma
ImmunityBio, Inc.
Phase 2 Recruiting
NCT04121455 2025-06-25
GLORIA
TME Pharma AG
Phase 1/2 Active not recruiting
NCT02017717 2025-04-04
CheckMate 143
Bristol-Myers Squibb
Phase 3 Completed
NCT01903330 2025-03-05
ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme
Epitopoietic Research Corporation
Phase 2 Active not recruiting
NCT02078648 2025-02-03
Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme
Stemline Therapeutics, Inc.
Phase 1/2 Completed
NCT04421378 2024-12-16
A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma
Karyopharm Therapeutics Inc
Phase 1/2 Terminated
NCT05118776 2024-10-31
Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM
Ascletis Pharma Inc
Phase 3 Active not recruiting
NCT04681677 2024-04-26
IORT
Xoft, Inc.
Phase 2 Terminated
NCT02052648 2024-03-27
Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
Lumos Pharma
Phase 1/2 Completed
NCT03149003 2023-11-15
A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy
Sumitomo Pharma America, Inc.
Phase 3 Completed
NCT05191784 2023-06-12
GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) Patients
Genexine, Inc.
Phase 2 Unknown
NCT01933815 2023-02-22
Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma
Cortice Biosciences, Inc.
Phase 1/2 Suspended
NCT00312728 2023-01-06
A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT)
Genentech, Inc.
Phase 2 Completed
NCT01137604 2022-09-29
A Study in Subjects With Recurrent Malignant Glioma
Eisai Inc.
Phase 2 Completed
NCT05476341 2022-07-27
A Phase I Clinical Trial of Bevacizumab Injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Completed
NCT02330562 2022-06-08
Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab
Celgene
Phase 1/2 Completed
NCT03554707 2022-02-08
SGT-53 in Children With Recurrent or Progressive CNS Malignancies
SynerGene Therapeutics, Inc.
Phase EARLY_PHASE1 Unknown
NCT00586508 2020-09-24
Trial of Enzastaurin and Bevacizumab in Participants With Recurrent Malignant Gliomas
Eli Lilly and Company
Phase 2 Completed
NCT01390948 2020-08-06
A Study of Bevacizumab (Avastin) in Combination With Temozolomide (TMZ) and Radiotherapy in Paediatric and Adolescent Participants With High-Grade Glioma
Hoffmann-La Roche
Phase 2 Completed
NCT01260506 2020-04-24
Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme
Vascular Biogenics Ltd. operating as VBL Therapeutics
Phase 1/2 Completed
NCT01967810 2020-02-25
ANG1005 in Patients With Recurrent High-Grade Glioma
Angiochem Inc
Phase 2 Completed
NCT01498328 2020-02-17
ReACT
Celldex Therapeutics
Phase 2 Completed
NCT02414165 2020-02-07
Toca5
Tocagen Inc.
Phase 2/3 Terminated
NCT01564914 2019-06-12
105GM201
Tracon Pharmaceuticals Inc.
Phase 2 Completed
NCT02511405 2018-10-23
GLOBE
Vascular Biogenics Ltd. operating as VBL Therapeutics
Phase 3 Completed
NCT03607643 2018-07-31
A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies
Leaf Vertical Inc.
Phase 1/2 Unknown
NCT01860638 2018-04-30
A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma
Hoffmann-La Roche
Phase 2 Completed
NCT01632228 2018-02-05
A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Participants With Recurrent Glioblastoma
Hoffmann-La Roche
Phase 2 Completed
NCT02047214 2018-01-31
Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy
Cortice Biosciences, Inc.
Phase 2 Terminated
NCT00943826 2017-09-25
A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma
Hoffmann-La Roche
Phase 3 Completed
NCT00345163 2017-05-16
BRAIN
Genentech, Inc.
Phase 2 Completed
NCT01248949 2017-03-29
A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors
MedImmune LLC
Phase 1 Completed
NCT01308684 2016-11-02
A Dose- and Efficacy-Finding Study of RO5323441 in Combination With Avastin (Bevacizumab) in Patients With Recurrent Glioblastoma
Hoffmann-La Roche
Phase 1 Completed
NCT02060955 2016-06-06
Randomized Phase 2 Study to Investigate Efficacy of ALECSAT in Patients With GBM Measured Compared to Avastin/Irinotecan
CytoVac A/S
Phase 2 Terminated
NCT01474239 2016-03-15
A Study of Avastin (Bevacizumab) And Fotemustine in Patients With Recurrent Glioblastoma
Hoffmann-La Roche
Phase 2 Completed
NCT00967330 2015-11-20
A Study of Avastin (Bevacizumab) and Irinotecan Versus Temozolomide Radiochemistry in Patients With Glioblastoma
Hoffmann-La Roche
Phase 2 Completed
NCT01115491 2014-12-08
A Study of Bevacizumab and Extended Treatment of Temozolomide in Patients With Recurrent Glioblastoma Multiforme
Hoffmann-La Roche
Phase 2 Completed
NCT01441388 2011-12-20
A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.
Pfizer
Phase 1 Withdrawn
NCT00906516 2009-05-21
Neuradiab® Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme
Bradmer Pharmaceuticals Inc.
Phase 2 Unknown
NCT00904852 2009-05-20
Safety Study of the Combination of Tandutinib With Temozolomide and Bevacizumab After Radiation and Temozolomide in Patients With Newly Diagnosed With Glioblastoma Multiforme
Millennium Pharmaceuticals, Inc.
Phase 1 Withdrawn